<DOC>
	<DOC>NCT00089635</DOC>
	<brief_summary>The purpose of this study is to determine that ABX-EGF (panitumumab) will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.</brief_summary>
	<brief_title>ABX-EGF (Panitumumab) Monotherapy in Subjects With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue biopsy) Metastatic colorectal carcinoma Eastern Cooperative Oncology Group of 0, 1 or 2 Documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer Radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen is required Bidimensionally measurable disease Tumor expressing low to negative levels of EGFr by immunohistochemistry At least 2 but no more than 3 prior chemotherapy regimens for metastatic colorectal cancer Adequate hematologic, renal and hepatic function Symptomatic brain metastases requiring treatment Patient with a history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis Use of systemic chemotherapy or radiotherapy within 30 days before enrollment Prior antiEGFr antibody therapy with the exception of the small molecule EGFr tyrosine kinase inhibitors, which are permitted Prior antitumor therapies including prior experimental agents or approved antitumor small molecules and biologics of short (less than 1 week) serum halflife within 30 days before enrollment, or prior experimental or approved proteins within 6 weeks before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Colon, Rectal Cancer</keyword>
	<keyword>ABX-EGF, Panitumumab, EGFr</keyword>
	<keyword>Immunex, Abgenix, Amgen</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Vectibix</keyword>
</DOC>